A good candidate as a tumour-associated antigen, and an attractive target for immunotherapy, is ErbB2 (also known as Her-2/Neu), a transmembrane tyrosine kinase receptor, overexpressed in breast carcinomas, for which it is a marker of poor prognosis (Slamon et al, 1987). Here, ERBB2 is linked to breast carcinoma.